Reprise Biomedical

Executive Summary

Reprise Biomedical is a privately held medical device company based in San Diego, CA, developing innovative biological matrices for wound care and soft tissue reinforcement. Leveraging its proprietary perfusion decellularization technology, the company creates acellular scaffolds from liver tissue that are designed to promote rapid cellular integration and healing in complex wounds, such as deep, tunneling, and surgical wounds. Founded in 2021, the company addresses significant unmet needs in advanced wound management, a market with substantial growth driven by an aging population and rising chronic disease prevalence. While still in early stages with no disclosed funding or commercial products, Reprise's platform holds promise to improve outcomes in challenging wound healing scenarios. However, the lack of clinical data and regulatory milestones introduces high uncertainty, and the company's ability to scale manufacturing and demonstrate clinical efficacy remains to be proven.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical trial initiation for lead wound scaffold product35% success
• Q4 2026FDA 510(k) submission for soft tissue reinforcement scaffold40% success
• Q2 2027Series A funding round closing50% success